Log In
BCIQ
Print this Print this
 

APL-130277

  Manage Alerts
Collapse Summary General Information
Company Sumitomo Dainippon Pharma Co. Ltd.
DescriptionSublingual thin film strip formulation of apomorphine, a small molecule dopamine receptor agonist
Molecular Target Dopamine receptor
Mechanism of ActionDopamine receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat "off" episodes in patients with Parkinson's disease (PD); Treat Parkinson's disease (PD)
Regulatory Designation U.S. - Fast Track (Treat "off" episodes in patients with Parkinson's disease (PD))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

4

$646.4M

$642.0M

$3.9M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today